2019 Jan “Expert Briefings” of Non-motor Symptoms: What’s New ? – Dr. Ronald Pfeiffer
Obstructive Symptoms: Treatment Alpha-1 adrenergic antagonists – Terazosin
2019 April Monthly Research Review, Science of Parkinson’s Disease (SoPD)
2019 May The Futile Hunt for Disease Modifying Therapies | Journal of Parkinson's Disease– by Ben Stecher
“…Also very recent reports of the benefits of terazosin and related compounds (Alpha-1-adrenergic blocking agents), used for the urinary symptoms of prostate disease and/or for hypertension - slows or prevents neuro-degeneration. A prospective study [TZ-PD Ph II 13 ppl trial for safety & tolerability - NCT03905811 ] confirmed benefits in a small number of patients. But the important research came from the Parkinson's Progression Markers Initiative database [ PPMI ], showing that this class of drug reduced hospital or clinic visits, disease complications, as well as specific scores for walking/gait/coordination measures, for and neuropsychiatric scores. The diagnosis of new Parkinson's disease was reduced by 38%.”
2019 Sept Science Daily – Big Data, bench science suggests dug may slow Parkinson’s progression in people . . .
sciencedaily.com/releases/2....
2019 Sept Parkinson’s News Today (PNT) Blood Pressure and Prostate Treatment May Prevent or Slow Parkinson’s . . .
2019 Sept Monthly Research Review – September, (SoPD)
“Chinese and US researchers published data suggesting that prostatic hyperplasia and hypertension drug, terazosin could be repurposed for Parkinson’s. Multiple PD models & human medical database evidence were presented in their report. They found that Terazosin activates phosphoglycerate kinase 1 (PGK1), one of the first enzymes in ATP production (the energy that cells run on). Treatment with terazosin rescued multiple neurotoxin & genetic models of Parkinson’s, and human dopamine neurons from LRRK2-G2019S patients that were grown in cell culture. MarketScan medical records database analysis found 2880 Parkinson’s patients with PD taking Terazosin (or similar) “had fewer PD-related diagnoses” than 15,409 individuals with PD + no Terazosin. PD-free individuals on Terazosin had reduced frequency of PD (0.62; P < 0.0001). A Phase II clinical trial for Terazosin in Parkinson’s is already being organised. It is a double blind, placebo controlled,12 weeks treatment in 20 people with PD (1:1 randomisation). Safety is the primary outcome, and it will be reporting in early 2020 (Click here to read the report, click here to read more about the clinical trial, click here to read the press release, click here for a good overview of this research, and click here to read an SoPD post on this topic).”
2019 Sept Prostate drug may slow Parkinson’s disease – BBC Online
2019 Sept 18th Repurposing from enlarged prostates to Parkinson’s (SoPD)
What is terazosin, what a receptor antagonist is, what the alpha-adrenergic receptor functions are, mitochondria, etc. etc.
2019 Sept Targeting neurons in the gastrointestinal track to treat Parkinson’s Disease – HealthUnlocked (HU)
(Drug mentioned of consequence in clinical trial AE)
2019 Oct The 2019 Linked Clinical Trials meeting (SoPD)
"There is a great deal of Parkinson’s preclinical research that is focused on clinically available drugs (for a good example see the recent SoPD post on the prostate drug Terazosin – click here to read that post). We don’t need to re-invent the wheel and come up with new formulations of old drugs to test whether a theory might work. That process requires years of research and longer clinical safety testing. We can use a clinically available drug, which will give us a proof of concept as to whether the hypothesized biology is important/relevant to Parkinson’s."
2019 Dec 2019 Year in Review (SoPD)
"In addition, there were a host of new clinical trial initiated, many of which are exploring entirely new experimental therapies. These include . . .
Terazosin – This prostatic hyperplasia and hypertension drug was found to enhance Phosphoglycerate kinase 1 (Pgk1) activation & a phase II trial was immediately initiated (Click here to read a SoPD post on this topic)."
2020 Jan The Road Ahead (SoPD)
"Another mitochondrial-focused clinical trial initiated in 2019 was a drug-repurposing study involving the prostatic hyperplasia and hypertension drug, Terazosin. Researchers published data suggesting that terazosin could rescue models of Parkinson’s by boosting energy production in mitochondria. A 12 week Phase II clinical trial for Terazosin in Parkinson’s was set up to assess safety of the drug in peope with Parkinson’s, and it is scheduled to finish in 2020 (Click here to read about the clinical trial and click here to read an SoPD post on this topic)."
2020 May Monthly Research Review – May 2020 (SoPD)
"New clinical study registered: Researchers will be exploring the effect of an adrenergic receptor blocker (Terazosin) on cardiac & striatal transporter uptake in pre-motor & symptomatic Parkinson’s (Click here to read more about this)."
2102 Feb Alpha Blockers for Enlarged Prostate May Lower Parkinson’s Risk (PNT)
2102 Feb Association of Glycolysis-Enhancing (alpha)-1 Blockers With Risk of Developing Parkinson’s Disease (JAMA)
jamanetwork.com/journals/ja...
2102 Feb Could a Prostate drug slow or stop Parkinson’s? by Clare Bale, Parkinson’s UK
2102 Feb Could prostate drugs reduce Parkinson’s disease risk? Medical News Today
2102 Feb Lower Risk of Parkinson’s Disease associated with Prostate Medication Hindustan Times
2102 Terazosin for Parkinson’s Disease (TZ-PD) – ClinicalTrials.gov
Considering the print type that Simon Stott is allocating to this drug, I'm inclined to think it worth watching going forward.
FMundo
Ambroxol update
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease
Probiotic, Solace PS128, Eases ‘Off’ Periods, Motor Symptoms in Trial (PRWEB) NOVEMBER 08, 2021
Subtypes: dysphagia
